Quick Answer
Milestone Pharmaceuticals Inc. reported Long Term Debt of $57.19 million for the year ending 2025.
- Milestone Pharmaceuticals Inc. showed an increase of +7.2% in Long Term Debt from 2024 to 2025.
- This data is from Milestone Pharmaceuticals Inc.'s annual report (Form 10-K), filed with the SEC on March 20, 2026.
- XBRL data for this metric is available from 2023 to 2025 (3 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2023: $47.32 million | Q2 2023: $48.07 million | Q3 2023: $48.92 million | Q1 2024: $50.64 million | Q2 2024: $51.53 million | Q3 2024: $52.43 million | Q1 2025: $54.29 million | Q2 2025: $55.24 million | Q3 2025: $56.21 million.
- Over the full 3 years of available data (2023 to 2025), Milestone Pharmaceuticals Inc.'s Long Term Debt has grown by 14.9%.
- Historical annual values: Fiscal year 2025: $57.19 million | Fiscal year 2024: $53.35 million | Fiscal year 2023: $49.77 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: